Format

Send to

Choose Destination
Clin Cancer Res. 2018 Dec 15;24(24):6107-6109. doi: 10.1158/1078-0432.CCR-18-1795. Epub 2018 Jul 24.

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition.

Author information

1
Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu.
2
Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

Abstract

Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could include MEK inhibitors. Combining BRAF and MEK inhibitors in this population may provide additional benefit.See related article by Dankner et al., p. 6483.

PMID:
30042206
PMCID:
PMC6295213
[Available on 2019-12-15]
DOI:
10.1158/1078-0432.CCR-18-1795

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center